An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer

An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer

Bladder cancer is among the five most common cancers diagnosed in the Western world and causes significant mortality and morbidity rates in affected patients. Therapeutic options to treat the disease in advanced muscle-invasive bladder cancer (MIBC) include cystectomy and chemotherapy. Neoadjuvant c...

Full description

Bibliographic Details
Main Authors: Evanguelos Xylinas, Melanie R. Hassler, Dazhong Zhuang, Martin Krzywinski, Zeynep Erdem, Brian D. Robinson, Olivier Elemento, Thomas Clozel, Shahrokh F. Shariat
Format: Article
Language:English
Published: MDPI AG 2016-09-01
Series:Biomolecules
Subjects:
HOXA9
urinary bladder neoplasms
drug resistance
neoadjuvant therapy
decitabine
Online Access:http://www.mdpi.com/2218-273X/6/3/37

Internet

http://www.mdpi.com/2218-273X/6/3/37

Similar Items